Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Issue 9 (September 2015)

• Record Type: Journal Article
• Authors: Kharfan-Dabaja, Mohamed A.; Labopin, Myriam; Bazarbachi, Ali; Socie, Gerard; Kroeger, Nicolaus; Blaise, Didier; Veelken, Hendrik; Bermudez, Arancha; Or, Reuven; Lioure, Bruno; Beelen, Dietrich; Fegueux, Nathalie; Hamladji, Rose Marie; Nagler, Arnon; Mohty, Mohamad
• Is Part Of: Leukemia research. Volume 39:Issue 9(2015:Sep.)
• Page Start: 933
• Page End: 937
• Publication Date: 2015-09
• Subjects: Leukemia -- Periodicals; Leukemia -- Periodicals; Leucémie -- Périodiques; Leukemia; Periodicals; Electronic journals; Electronic journals; 616.9941905
• DOI: 10.1016/j.leukres.2015.04.009
• Languages: English
• ISSNs: 0145-2126

Abstract

<abstract abstract-type="author-highlights" id="abs0005"> <title id="sect0005">Highlights</title> <sec> <p id="spar0005"> <list id="lis0005"> <list-item id="lsti0005"> <label></label> <p id="par0005">In AML in CR2, FB4 (vs. FB2) as a regimen for allo-HCT improves PFS and OS.</p> </list-item> <list-item id="lsti0010"> <label></label> <p id="par0010">Longer time from diagnosis to allograft yields better LFS and OS and less relapse.</p> </list-item> <list-item id="lsti0015"> <label></label> <p id="par0015">A 2-fold higher incidence of aGVHD was observed with FB4 (28% vs. 15%, <italic>p</italic> = 0.08).</p> </list-item> </list> </p> </sec> </abstract>